Mergers and Acquisitions

Glaser Weil has extensive experience working with our clients to navigate the ever complex and fastmoving mergers and acquisitions landscape.

We structure both the overarching framework of the deals and handle the intricate details of both public and private acquisitions, exchange offers and “going private” transactions, as well as various multi-step acquisitions that require restructuring of companies, corporate workouts and other industry-specific transactions. Additionally, the firm has had continued success in achieving valuations in excess of the originally sought sales price.

In the extremely time-sensitive, often volatile world of M&A, our technical know-how and ability to efficiently form cross-disciplinary teams allows our clients to close their deals on time — and within their strategy, needs and goals.

Areas of Focus

• Corporate reorganizations
• Divestitures
• Domestic and cross-border mergers and acquisitions
• Going-private transactions
• Joint ventures and strategic business combinations/alliances
• Leveraged buyouts
• Private equity investments and acquisitions
• Recapitalizations
• Regulatory liaisons and approvals
• Sale of control
• Share exchanges
• Special committee representations

A sampling of Glaser Weil's M&A experience includes its representation of:

• Wyatt Technology in its $1.36 billion acquisition by Waters Corporation (NYSE: WAT), a global pharmaceutical leader in analytical instruments and software.
• Carl Zeiss Meditec AG in connection with its proposed $1.6 billion acquisition of a division of Bausch & Lomb.
• A waste disposal company with an enterprise value in excess of $1.4 billion in connection with its sale. Targeted sales price $850 million.
• A minority owner of the New York Yankees in connection with its sale which, at the time, was the highest price per unit in the history of the New York Yankees and no investment banker was involved.
• Part of the ownership group in connection with the acquisition of the Sacramento Kings for $500 million.
• MaxIT, a Riordan, Lewis & Haden portfolio company, in connection with its sale to SAIC for $500 million. Targeted sales price approximately $300 million.
• Alacer Corporation (manufacturer of Emergen-C) in connection with its sale to Pfizer, helping to achieve a sale price 40% above initial estimates.
• An ownership group in connection with the acquisition of the New Orleans Hornets for $350 million.
• A software company in its sale for $320 million. Targeted sales price $220 million.
• A medical device company in its sale for $300 million. Original offered purchase price $225 million.
• American Title, a publicly traded (NASDAQ) title insurance company, in its $182 million merger with Fidelity Title.
• Equityholders of Blackstone Consulting, Inc., and J.B. Properties, Inc., in the sale of 49% of their interests in the companies to USAGM Acquisition, LLC.
• TriMed Inc., a global developer of market-leading orthopedic implants, in the sale of a majority interest to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners.
• Horizon/CJK in its joint venture with Fortress Investment Group to acquire United Oil Co.
• INVO Bioscience, Inc. (Nasdaq: INVO), a global leader in expanding access to advanced fertility treatment, in an all-stock reverse merger agreement with NAYA Biosciences Inc.
• SC Fuels, a leading petroleum distributor, in its swap of United Fuel & Energy in exchange for Pilot Energy’s California land-based business and southwest operations.

Results